Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 107-119 , May 2009

Reconstruction of Defects Caused by Bisphosphonate-Induced Osteonecrosis of the Jaws

  • Robert E. Marx, DDS

      Affiliations

    • Professor of Surgery, Chief and Director of Research, Division of Oral and Maxillofacial Surgery, University of Miami Miller School of Medicine, Miami, FL
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Marx: Miller School of Medicine, Division of Oral and Maxillofacial Surgery, University of Miami, 9380 SW 150 Street, Suite 190, Miami, FL 33137

References 

  1. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369
  2. Migliorati CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate-associated osteonecrosis (An American Academy of Oral Medicine Position Paper). JADA. 2005;136:1658
  3. Kruger CD, Weat PM, Sargent M, et al. Bisphosphonate-induced osteonecrosis of the jaw. Ann Pharmacother. 2007;41:276
  4. Hellenstein JW, Marek CL. Bisphosphonate induced osteochemonecrosis of the jaws: An ounce of prevention may be worth a pound of cure. Spec Care Dentist. 2006;25:8
  5. Throndson RR, Healy SM, Zwickey MR. Bisphosphonate-induced osteonecrosis of the jaws. Tex Dent J. 2005;122:960
  6. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of actions fo bisphosphonates. Cancer. 2000;88:2961
  7. Van Beek ER, Lowck CWGM, Papapoulos SE. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic-cells: The role of protein geranlyations in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone. 2002;30:64
  8. Edwards BJ, Gounder M, McKoy JM, et al. Bisphosphonate use and osteonecrosis fo the jaw: Pharmacovigilance and reporting of this serious adverse event. Lancet Oncol. 2008;9:1166
  9. In:  Tierney JM,  McPhee SJ,  Papadakis MA editor. Lang Current Medical Diagnosis and Treatment. (ed 39). New York: Lange Medical Books/McGraw Hill; 2000;
  10. Adoina CV, Zerwelsh JE, Rao S, et al. Severely suppressed bone turnover (A potential complication of alendronate therapy). J Clin Endocrinol Metab. 2005;90:1294
  11. Lasseter KC, Porras AG, Denker A, et al. Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. Clin Drug Invest. 2005;25:107
  12. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg. 2005;63:1567
  13. Ruggeiro SL, Mekrota B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2004;62:527
  14. Marx RE, Cillo JE, Ulloa J. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397
  15. Marx RE, Smith BR. An improved technique for development of the pectoralis major myocutaneous flap. J Oral Maxillofac Surg. 1990;48:1168
  16. Rosen HN, Moses AC, Garber J, et al. Utility of biochemical markers of bone turnover in the follow up of patients treated with bisphosphonates. Calcif Tissue Int. 1998;63:363
  17. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:18
  18. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after five years of treatment (The fracture intervention trial long-term extension (flex). A randomized trial). JAMA. 2006;296:2727
  19. Rosen HN, Moses AC, Garber J, et al. Serum CTX (A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy). Calcif Tissue Int. 2000;66:100

 Dr Marx is a paid consultant for Medtronics and is a shareholder for Harvest Technologies. He receives royalties from Quintessence Publishing. Stryker, Synthes Maxillofacial, Biomet 3i, and Biomet Microfixation provide residency support at the Miami School of Medicine, although Dr Marx receives no personal monies from this funding. Dr Marx is a voluntary unpaid expert witness for Osborn LLC attorneys in litigation against Novartis Pharmaceuticals and Merck Co. In this article Dr Marx discusses off-label use for Infuse Bone Graft for reconstruction.

PII: S0278-2391(08)01835-1

doi: 10.1016/j.joms.2008.12.007

Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 107-119 , May 2009

Article Tools

* Image Usage & Resolution